<DOC>
	<DOCNO>NCT02838862</DOCNO>
	<brief_summary>Although gastroenteropancreatic neuroendocrine neoplasia ( GEP-NEN ) consider year rare tumor , incidence increase . Due potential early metastasis heterogenous response therapy , tumor important clinical entity . A major problem remain impossibility adequately predict tumor ' response treatment , preclude individualized therapy . Further , method efficiently screen tumor . Protein base analysis ( proteomic analysis ) gain interest method address problematic . The present study design investigate epidemiologic data patient GEP-NEN answer follow question use proteomic analysis apply exist pathology specimen ( paraffin-embedded specimen , FFPE ) : possible explore protein signatures type tumor ? Is response therapy predictable use specific protein signature ? Is tumor 's tendency metastasize relate specific protein signature ?</brief_summary>
	<brief_title>Identification Biomarker Profiles GEP-NEN Patients</brief_title>
	<detailed_description>Gastroenteropancreatic neuroendocrine neoplasia ( GEP-NEN ) consider year rare tumor . In last year however , incidence increase ( 3,65 / 100.000 / year ) [ Lawrence et al. , 2011 ; Friling et al , 2014 ] . These tumor important clinical entity : 1 ) 40-95 % tumor metastasize diagnosis , 2 ) evidence-based data deal therapeutic strategy screen still scarce . A central problem remain impossibility adequately predict response surgery , chemotherapy , radiochemotherapy , peptid-receptor-based Radiotherapy biotherapy , preclude individualize therapy ( precision medicine ) [ Rinke et al. , 2014 ] . An actual research topic patient identification patient marker allow response prediction . Moreover , researcher try identify tumor marker patient unknown primary order locate origin metastasis . Further , identification tumor specific marker would allow development screen strategy GEP-NEN . Due ability technique describe biological heterogenity tumor , proteomics ( protein base analysis method ) promise present problematic [ Bezabeh et al. , 2014 ; LÃ¶hr et al. , 2006 ; Pan et al. , 2013 ] . The present study design investigate epidemiologic data patient GEP-NEN answer follow question use proteomic analysis ( MALDI-MS ) apply exist pathology specimen ( paraffin-embedded specimen , FFPE ) : possible explore protein signatures type tumor ? Is response therapy predictable use specific protein signature ? Is tumor 's tendency metastasize relate specific protein signature ? The present investigation explore GEP-NEN database/register follow institution : University Hospital Schleswig Holstein , University hospital Freiburg , Agaplesion Hospital Rotenburg . The pathology specimens study register-population , identify biobank pathology-institutes participate hospital investigate use MALDI-MS technique .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>GEPNEN Absence histological confirmation diagnosis Absence pathology specimen evaluate use MALDIMS</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>MALDI-MS</keyword>
	<keyword>Proteomics</keyword>
	<keyword>Biomarkers , Tumor</keyword>
	<keyword>Precision Medicine</keyword>
</DOC>